Global Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 28
1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.3 OVERVIEW OF GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 28
1.4 LIMITATIONS 30
1.5 MARKETS COVERED 30
2 MARKET SEGMENTATION 33
2.1 MARKETS COVERED 33
2.2 GEOGRAPHICAL SCOPE 34
2.3 YEARS CONSIDERED FOR THE STUDY 35
2.4 CURRENCY AND PRICING 35
2.5 DBMR TRIPOD DATA VALIDATION MODEL 36
2.6 MULTIVARIATE MODELLING 39
2.7 PRODUCT AND SERVICES LIFELINE CURVE 39
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 40
2.9 DBMR MARKET POSITION GRID 41
2.10 MARKET END USER COVERAGE GRID 42
2.11 VENDOR SHARE ANALYSIS 43
2.12 SECONDARY SOURCES 44
2.13 ASSUMPTIONS 44
3 EXECUTIVE SUMMARY 45
4 PREMIUM INSIGHTS 47
4.1 PESTEL ANALYSIS 50
4.2 PORTER'S FIVE FORCES 51
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 52
5 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 53
6 MARKET OVERVIEW 56
6.1 DRIVERS 58
6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 58
6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 59
6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 60
6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 60

6.2 RESTRAINTS 61
6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 61
6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 61
6.3 OPPORTUNITIES 62
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 62
6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 62
6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 64
6.4 CHALLENGES 65
6.4.1 PRODUCT RECALLS 65
6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 65
7 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 66
7.1 OVERVIEW 67
7.2 REAGENTS & CONSUMABLES 70
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 70
7.4 SERVICES 71
8 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 73
8.1 OVERVIEW 74
8.2 VIRAL 77
8.2.1 CORONAVIRUS 78
8.2.2 INFLUENZA VIRUS 78
8.2.3 ADENOVIRUS 78
8.2.4 RHINOVIRUS 78
8.2.5 ROTAVIRUS 78
8.2.6 OTHERS 78
8.3 BACTERIAL 79
8.3.1 PNEUMONIAE 80
8.3.2 BORDETELLA PERTUSSIS 80
8.3.3 STAPHYLOCOCCUS 80
8.3.4 OTHERS 80
8.4 PARASITES 80
8.5 FUNGAL 81

9 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 83
9.1 OVERVIEW 84
9.2 RESPIRATORY INFECTIONS 87
9.3 GASTROENTERITIS 88
9.4 SEXUALLY TRANSMITTED INFECTIONS 88
9.5 SEPSIS 89
9.6 MENINGITIS 90
9.7 OTHERS 91
10 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 93
10.1 OVERVIEW 94
10.2 RESPIRATORY PANEL 97
10.3 GI-ENTERIC PANEL 97
10.4 SEXUALLY TRANSMITTED DISEASE PANEL 98
10.5 BLOOD-SEPSIS PANEL 99
10.6 MENINGITIS PANEL 100
10.7 OTHERS 101
11 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 102
11.1 OVERVIEW 103
11.2 HOSPITALS 106
11.3 CLINICAL LABORATORIES 106
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 107
11.5 RESEARCH INSTITUTES 108
11.6 OTHERS 109
12 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 110
12.1 OVERVIEW 111
12.2 NORTH AMERICA 116
12.2.1 U.S. 123
12.2.2 CANADA 126
12.2.3 MEXICO 129

12.3 EUROPE 132
12.3.1 GERMANY 139
12.3.2 U.K. 142
12.3.3 FRANCE 145
12.3.4 ITALY 148
12.3.5 SPAIN 151
12.3.6 NETHERLANDS 154
12.3.7 SWITZERLAND 157
12.3.8 RUSSIA 160
12.3.9 BELGIUM 163
12.3.10 TURKEY 166
12.3.11 REST OF EUROPE 169
12.4 ASIA-PACIFIC 170
12.4.1 CHINA 177
12.4.2 JAPAN 180
12.4.3 INDIA 183
12.4.4 SOUTH KOREA 186
12.4.5 AUSTRALIA 189
12.4.6 SINGAPORE 192
12.4.7 THAILAND 195
12.4.8 MALAYSIA 198
12.4.9 INDONESIA 201
12.4.10 PHILIPPINES 204
12.4.11 REST OF ASIA-PACIFIC 207
12.5 SOUTH AMERICA 208
12.5.1 BRAZIL 215
12.5.2 ARGENTINA 218
12.5.3 REST OF SOUTH AMERICA 221
12.6 MIDDLE EAST AND AFRICA 222
12.6.1 SOUTH AFRICA 229
12.6.2 SAUDI ARABIA 232
12.6.3 U.A.E 235
12.6.4 ISRAEL 238
12.6.5 EGYPT 241
12.6.6 REST OF MIDDLE EAST AND AFRICA 244

13 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 245
13.1 COMPANY SHARE ANALYSIS: GLOBAL 245
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 246
13.3 COMPANY SHARE ANALYSIS: EUROPE 247
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 248
14 SWOT ANALYSIS 249
15 COMPANY PROFILE 250
15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMRIEUX SA) 250
15.1.1 COMPANY SNAPSHOT 250
15.1.2 REVENUE ANALYSIS 250
15.1.3 COMPANY SHARE ANALYSIS 251
15.1.4 PRODUCT PORTFOLIO 251
15.1.5 RECENT DEVELOPMENTS 252
15.2 F. HOFFMANN-LA ROCHE LTD 253
15.2.1 COMPANY SNAPSHOT 253
15.2.2 REVENUE ANALYSIS 253
15.2.3 COMPANY SHARE ANALYSIS 254
15.2.4 PRODUCT PORTFOLIO 254
15.2.5 RECENT DEVELOPMENT 255
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 256
15.3.1 COMPANY SNAPSHOT 256
15.3.2 RECENT FINANCIALS 256
15.3.3 COMPANY SHARE ANALYSIS 257
15.3.4 PRODUCT PORTFOLIO 257
15.3.5 RECENT DEVELOPMENT 258
15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 259
15.4.1 COMPANY SNAPSHOT 259
15.4.2 RECENT FINANCIALS 259
15.4.3 COMPANY SHARE ANALYSIS 260
15.4.4 PRODUCT PORTFOLIO 260
15.4.5 RECENT DEVELOPMENTS 261
15.5 QIAGEN 262
15.5.1 COMPANY SNAPSHOT 262
15.5.2 RECENT FINANCIALS 262
15.5.3 COMPANY SHARE ANALYSIS 263
15.5.4 PRODUCT PORTFOLIO 263
15.5.5 RECENT DEVELOPMENT 263

15.6 ABBOTT 264
15.6.1 COMPANY SNAPSHOT 264
15.6.2 REVENUE ANALYSIS 264
15.6.3 PRODUCT PORTFOLIO 265
15.6.4 RECENT DEVELOPMENT 265
15.7 AKONNI BIOSYSTEMS, INC. 266
15.7.1 COMPANY SNAPSHOT 266
15.7.2 PRODUCT PORTFOLIO 266
15.7.3 RECENT DEVELOPMENT 266
15.8 APPLIED BIOCODE, INC. 267
15.8.1 COMPANY SNAPSHOT 267
15.8.2 PRODUCT PORTFOLIO 267
15.8.3 RECENT DEVELOPMENTS 268
15.9 BD 269
15.9.1 COMPANY SNAPSHOT 269
15.9.2 REVENUE ANALYSIS 269
15.9.3 PRODUCT PORTFOLIO 270
15.9.4 RECENT DEVELOPMENTS 270
15.10 BIOCARTIS 271
15.10.1 COMPANY SNAPSHOT 271
15.10.2 REVENUE ANALYSIS 271
15.10.3 PRODUCT PORTFOLIO 272
15.10.4 RECENT DEVELOPMENT 272
15.11 BIO-RAD LABORATORIES, INC. 273
15.11.1 COMPANY SNAPSHOT 273
15.11.2 REVENUE ANALYSIS 273
15.11.3 PRODUCT PORTFOLIO 274
15.11.4 RECENT DEVELOPMENT 274
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 275
15.12.1 COMPANY SNAPSHOT 275
15.12.2 REVENUE ANALYSIS 275
15.12.3 PRODUCT PORTFOLIO 276
15.12.4 RECENT DEVELOPMENT 276
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 277
15.13.1 COMPANY SNAPSHOT 277
15.13.2 RECENT FINANCIALS 277
15.13.3 PRODUCT PORTFOLIO 278
15.13.4 RECENT DEVELOPMENTS 278

15.14 HOLOGIC, INC. 279
15.14.1 COMPANY SNAPSHOT 279
15.14.2 RECENT FINANCIALS 279
15.14.3 PRODUCT PORTFOLIO 280
15.14.4 RECENT DEVELOPMENT 280
15.15 MIRXES PTE LTD. 281
15.15.1 COMPANY SNAPSHOT 281
15.15.2 PRODUCT PORTFOLIO 281
15.15.3 RECENT DEVELOPMENT 281
15.16 NANMIX, INC. 282
15.16.1 COMPANY SNAPSHOT 282
15.16.2 PRODUCT PORTFOLIO 282
15.16.3 RECENT DEVELOPMENT 282
15.17 PROMINEX INC. 283
15.17.1 COMPANY SNAPSHOT 283
15.17.2 PRODUCT PORTFOLIO 283
15.17.3 RECENT DEVELOPMENT 283
15.18 QUANTUMDX GROUP LTD. 284
15.18.1 COMPANY SNAPSHOT 284
15.18.2 PRODUCT PORTFOLIO 284
15.18.3 RECENT DEVELOPMENTS 284
15.19 SEEGENE INC. 285
15.19.1 COMPANY SNAPSHOT 285
15.19.2 REVENUE ANALYSIS 285
15.19.3 PRODUCT PORTFOLIO 286
15.19.4 RECENT DEVELOPMENTS 289
15.20 SIEMENS HEALTHCARE GMBH 290
15.20.1 COMPANY SNAPSHOT 290
15.20.2 RECENT FINANCIALS 290
15.20.3 PRODUCT PORTFOLIO 291
15.20.4 RECENT DEVELOPMENT 291
15.21 THERMOFISHER SCIENTIFIC INC. 292
15.21.1 COMPANY SNAPSHOT 292
15.21.2 RECENT FINANCIALS 292
15.21.3 PRODUCT PORTFOLIO 293
15.21.4 RECENT DEVELOPMENT 293
16 QUESTIONNAIRE 294
17 RELATED REPORTS 297